君实生物公告将于9月14日召开2026年半年度业绩说明会

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility
for the contents of this announcement, make no representation as to its accuracy or completeness and expressly
disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the
contents of this announcement.

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People ’s Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT
This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of
Securities on The Stock Exchange of Hong Kong Limited.
Reference is made to the “ Shanghai Junshi Biosciences Co., Ltd.* Announcement on the
Convening of the 2026 Interim Results Briefing” published by Shanghai Junshi Biosciences Co.,
Ltd.* on the website of the Shanghai Stock Exchange, for reference purpose only.
By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman
Shanghai, the PRC, 4 September 2026

As at the date of this announcement, the Board of Directors of the Company comprises
Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Wang Gang
and Dr. Li Xin as executive Directors; Dr. Yao Sheng and Mr. Tang Yi as non-executive Directors;
and Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun, Dr. Yang Jin and Mr. Chen Liang as
independent non-executive Directors.
*

For identification purposes only

Stock code: 688180

Stock Abbreviation: Junshi Bio

Announcement No.: Lin 2026-054

Shanghai Junshi Biosciences Co., Ltd.*
Announcement on the Convening of the 2026 Interim
Results Briefing
The board of directors and all directors of the Company warrant that the contents
of the announcement do not contain any false and misleading representation or material
omission, and shall undertake legal liabilities in accordance with the law for the
truthfulness, accuracy and completeness of the contents herein.

Important Notice:
⚫ Time of the briefing: 10:00-11:00, 14 September 2026 (Monday)
⚫ Venue of the briefing: Shanghai Stock Exchange Roadshow Center
(https://roadshow.sseinfo.com)
⚫ Mode of the briefing: SSE Roadshow Center online interaction
⚫ Investors are invited to ask questions through the “Pre-collection of Questions”
section at the homepage of the SSE Roadshow Center website or send questions to the
email

of

Shanghai

Junshi

Biosciences

Co.,

Ltd.*

(the

“Company”)

(info@junshipharma.com) in advance from 7 September 2026 (Monday) to 16:00, 11
September 2026 (Friday). The Company will respond to questions that are of general
concern to investors at the briefing.

The Company has disclosed its 2026 interim report on the website of the Shanghai
Stock Exchange (www.sse.com.cn) on 27 August 2026. In order to facilitate investors
to have a more comprehensive and in-depth understanding of the operating results and
financial status of the Company for the first half of 2026, the Company plans to convene
the 2026 interim results briefing at 10:00-11:00, 14 September 2026, and communicate
with investors about their concerns.

I. Type of the Briefing
This investor briefing will be held in the form of online interaction. The Company
will interact and communicate with investors with regard to the operating results and
financial indicators for the first half of 2026. Questions that are of general concern to
investors will be answered subject to restrictions under the information disclosure rules.
II. Time and Venue of the Briefing
(I) Time of the briefing: 10:00-11:00, 14 September 2026 (Monday)
(II) Venue of the briefing: SSE Roadshow Center
(III) Mode of the briefing: SSE Roadshow Center online interaction
III. Attendees
Attendees of the briefing include: Ms. Zou Jianjun (Executive Director, General
Manager, Chief Executive Officer and Core Technical Personnel), Mr. Li Zhongxian
(Independent Non-Executive Director), Mr. Xu Baohong (Financial Director), and Mr.
Wang Zhengyu (Secretary of the Board of Directors) (subject to changes in case of any
special circumstances).
IV. Ways of Participation by Investors
(I) Investors may access the website of the SSE Roadshow Center
(https://roadshow.sseinfo.com) at 10:00-11:00, 14 September 2026 (Monday) via the
Internet to participate the briefing online. The Company will respond to the questions
of the investors in a timely manner.
(II) Investors are invited to ask the Company questions through the “Pre-collection
of Questions” section (https://roadshow.sseinfo.com/preCallQa) at the homepage of the
SSE Roadshow Center website by selecting this event according to the event time or
send questions to the Company’s email (info@junshipharma.com) in advance from 7
September 2026 (Monday) to 16:00, 11 September 2026 (Friday). The Company will
respond to questions that are of general concern to investors at the briefing.
V. Contact Details for the Briefing
Contact Department: Securities Department
Contact Tel.: 021-61058800-1153
Contact Email: info@junshipharma.com

VI. Others Matters
Upon the convening of the investor briefing, investors may review the convening
details and key contents of the investor briefing at the website of the SSE Roadshow
Center (https://roadshow.sseinfo.com).

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*
Board of Directors
5 September 2026

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性
或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚
賴該等內容而引致的任何損失承擔任何責任。

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司
（於中華人民共和國註冊成立的股份有限公司）

（股份代號：1877）

海外監管公告
本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條規則作出。
茲載列上海君實生物醫藥科技股份有限公司在上海證券交易所網站刊發之《上海
君實生物醫藥科技股份有限公司關於召開2026 年半年度業績說明會的公告》，僅
供參閱。
承董事會命
上海君實生物醫藥科技股份有限公司
熊俊先生
主席
中國，上海，2026年9月4日

於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、
李聰先生、張卓兵先生、王剛博士及李鑫博士；非執行董事姚盛博士及湯毅先
生；以及獨立非執行董事馮曉源博士、酈仲賢先生、魯琨女士、楊勁博士及陳良
先生。
* 僅供識別之用

证券代码：688180

证券简称：君实生物

公告编号：临 2026-054

上海君实生物医药科技股份有限公司
关于召开 2026 年半年度业绩说明会的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述
或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。

重要内容提示：
 会议召开时间：2026 年 9 月 14 日（星期一）10:00-11:00
 会议召开地点：上海证券交易所上证路演中心（网址：
https://roadshow.sseinfo.com）
 会议召开方式：上证路演中心网络互动
 投资者可于 2026 年 9 月 7 日（星期一）至 2026 年 9 月 11 日（星期五）
16:00 前登录上证路演中心网站首页点击“提问预征集”栏目或通过上海君实生
物医药科技股份有限公司（以下简称“公司”）邮箱 info@junshipharma.com 进
行提问。公司将在说明会上对投资者普遍关注的问题进行回答。

公司已于 2026 年 8 月 27 日在上海证券交易所网站（www.sse.com.cn）披露
公司 2026 年半年度报告，为便于广大投资者更全面深入地了解公司 2026 年半年
度的经营成果、财务状况，公司计划于 2026 年 9 月 14 日 10:00-11:00 召开 2026
年半年度业绩说明会，就投资者关心的问题进行交流。
一、说明会类型
本次投资者说明会以网络互动的形式召开，公司将针对 2026 年半年度经营
成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范
围内就投资者普遍关注的问题进行回答。
二、说明会召开的时间、地点
（一）会议召开时间：2026 年 9 月 14 日（星期一）10:00-11:00
（二）会议召开地点：上证路演中心

（三）会议召开方式：上证路演中心网络互动
三、参加人员
参加此次说明会人员包括：执行董事、总经理、首席执行官、核心技术人员
邹建军女士，独立非执行董事郦仲贤先生，财务总监许宝红先生，董事会秘书王
征宇先生（如有特殊情况，参会人员将可能进行调整）。
四、投资者参加方式
（一）投资者可在 2026 年 9 月 14 日（星期一）上午 10:00-11:00，通过互联
网登录上证路演中心（https://roadshow.sseinfo.com），在线参与本次业绩说明会，
公司将及时回答投资者的提问。
（二）投资者可于 2026 年 9 月 7 日（星期一）至 2026 年 9 月 11 日（星期
五 ） 16:00 前 登 录 上 证 路 演 中 心 网 站 首 页 ， 点 击 “ 提 问 预 征 集 ” 栏 目
（https://roadshow.sseinfo.com/preCallQa），根据活动时间，选中本次活动或通过
公司邮箱 info@junshipharma.com 向公司提问，公司将在说明会上对投资者普遍
关注的问题进行回答。
五、联系人及咨询办法
联系部门：证券部
联系电话：021-61058800-1153
联系邮箱：info@junshipharma.com
六、其他事项
本次投资者说明会召开后，投资者可以通过上证路演中心
（https://roadshow.sseinfo.com）查看本次投资者说明会的召开情况及主要内容。

特此公告。

上海君实生物医药科技股份有限公司
董事会
2026 年 9 月 5 日